{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["NSAIDs", "apoptosis", "cell cycle", "cytotoxicity", "docking study", "indolizine", "pyrrolizine"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34770990", "DateCompleted": {"Year": "2021", "Month": "12", "Day": "03"}, "DateRevised": {"Year": "2021", "Month": "12", "Day": "14"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "10", "Day": "30"}], "Language": ["eng"], "ELocationID": ["6582", "10.3390/molecules26216582"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "26", "Issue": "21", "PubDate": {"Year": "2021", "Month": "Oct", "Day": "30"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "Pyrrolizine/Indolizine-NSAID Hybrids: Design, Synthesis, Biological Evaluation, and Molecular Docking Studies.", "Abstract": {"AbstractText": ["In the current study, eight new hybrids of the NSAIDs, ibuprofen and ketoprofen with five pyrrolizine/indolizine derivatives were designed and synthesized. The chemical structures of these hybrids were confirmed by spectral and elemental analyses. The antiproliferative activities of these hybrids (5 \u03bcM) was investigated against MCF-7, A549, and HT-29 cancer cell lines using the cell viability assay, MTT assay. The results revealed 4-71% inhibition of the growth of the three cancer cell lines, where <b>8a</b>,<b>e</b>,<b>f</b> were the most active. In addition, an investigation of the antiproliferative activity of <b>8a</b>,<b>e</b>,<b>f</b> against MCF-7 cells revealed IC<sub>50</sub> values of 7.61, 1.07, and 3.16 \u03bcM, respectively. Cell cycle analysis of MCF-7 cells treated with the three hybrids at 5 \u03bcM revealed a pro-apoptotic increase in cells at preG1 and cell cycle arrest at the G1 and S phases. In addition, the three hybrids induced early apoptotic events in MCF-7 cells. The results of the molecular docking of the three hybrids into COX-1/2 revealed higher binding free energies than their parent compounds <b>5a</b>,<b>c</b> and the co-crystallized ligands, ibuprofen and SC-558. The results also indicated higher binding free energies toward COX-2 over COX-1. Moreover, analysis of the binding modes of <b>8a</b>,<b>e</b>,<b>f</b> into COX-2 revealed partial superposition with the co-crystallized ligand, SC-558 with the formation of essential hydrogen bonds, electrostatic, or hydrophobic interactions with the key amino acid His90 and Arg513. The new hybrids also showed drug-likeness scores in the range of 1.06-2.03 compared to ibuprofen (0.65) and ketoprofen (0.57). These results above indicated that compounds <b>8a</b>,<b>e</b>,<b>f</b> deserve additional investigation as potential anticancer candidates."]}, "AuthorList": [{"Identifier": ["0000-0003-1348-6567"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutics, Faculty of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}], "LastName": "Abourehab", "ForeName": "Mohammed A S", "Initials": "MAS"}, {"Identifier": ["0000-0002-8845-2786"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}], "LastName": "Alqahtani", "ForeName": "Alaa M", "Initials": "AM"}, {"Identifier": ["0000-0003-4048-1526"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}], "LastName": "Almalki", "ForeName": "Faisal A", "Initials": "FA"}, {"Identifier": ["0000-0001-5814-0784"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Sharjah Institute for Medical Research, University of Sharjah, Sharjah 27272, United Arab Emirates."}], "LastName": "Zaher", "ForeName": "Dana M", "Initials": "DM"}, {"Identifier": ["0000-0003-4770-9319"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, Faculty of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Department of Pharmacology, Medicinal and Aromatic Plants Research Institute, National Center for Research, Khartoum 2404, Sudan."}], "LastName": "Abdalla", "ForeName": "Ashraf N", "Initials": "AN"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medicinal Chemistry Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt."}], "LastName": "Gouda", "ForeName": "Ahmed M", "Initials": "AM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia 61519, Egypt."}], "LastName": "Beshr", "ForeName": "Eman A M", "Initials": "EAM"}], "GrantList": [{"GrantID": "19-MED-1-01-0024", "Agency": "Deanship of Scientific Research at Umm Al-Qura University, Makkah, KSA", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Anti-Inflammatory Agents, Non-Steroidal"}, {"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Indolizines"}, {"RegistryNumber": "0", "NameOfSubstance": "Pyrroles"}, {"RegistryNumber": "274-40-8", "NameOfSubstance": "indolizine"}], "MeshHeadingList": [{"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Anti-Inflammatory Agents, Non-Steroidal"}, {"QualifierName": ["chemical synthesis", "chemistry", "pharmacology"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": ["drug effects"], "DescriptorName": "Apoptosis"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Cycle Checkpoints"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Proliferation"}, {"QualifierName": [], "DescriptorName": "Dose-Response Relationship, Drug"}, {"QualifierName": [], "DescriptorName": "Drug Screening Assays, Antitumor"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Indolizines"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Pyrroles"}, {"QualifierName": [], "DescriptorName": "Tumor Cells, Cultured"}], "CoiStatement": "Authors declared that there is no conflict of interest and have approved the article."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Sun J., Wei Q., Zhou Y., Wang J., Liu Q.H., Xu H. A systematic analysis of FDA-approved anticancer drugs. BMC Syst. Biol. 2017;11:87. doi: 10.1186/s12918-017-0464-7.", "ArticleIdList": ["10.1186/s12918-017-0464-7", "PMC5629554", "28984210"]}, {"Citation": "Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer Statistics, 2021. CA Cancer J. Clin. 2021;71:7\u201333. doi: 10.3322/caac.21654.", "ArticleIdList": ["10.3322/caac.21654", "33433946"]}, {"Citation": "Bayat Mokhtari R., Homayouni T.S., Baluch N., Morgatskaya E., Kumar S., Das B., Yeger H. Combination therapy in combating cancer. Oncotarget. 2017;8:38022\u201338043. doi: 10.18632/oncotarget.16723.", "ArticleIdList": ["10.18632/oncotarget.16723", "PMC5514969", "28410237"]}, {"Citation": "Ramos A., Sadeghi S., Tabatabaeian H. Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them. Int. J. Mol. Sci. 2021;22:9451. doi: 10.3390/ijms22179451.", "ArticleIdList": ["10.3390/ijms22179451", "PMC8430957", "34502361"]}, {"Citation": "Damiana T.S.T., Dalm S.U. Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer. Pharmaceutics. 2021;13:674. doi: 10.3390/pharmaceutics13050674.", "ArticleIdList": ["10.3390/pharmaceutics13050674", "PMC8151894", "34067215"]}, {"Citation": "Smith K.S., Folz B.A., Adams E.G., Bhuyan B.K. Synergistic and additive combinations of several antitumor drugs and other agents with the potent alkylating agent adozelesin. Cancer Chemother. Pharmacol. 1995;35:471\u2013482. doi: 10.1007/BF00686831.", "ArticleIdList": ["10.1007/BF00686831", "7533669"]}, {"Citation": "Palmer A.C., Sorger P.K. Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy. Cell. 2017;171:1678\u20131691.e13. doi: 10.1016/j.cell.2017.11.009.", "ArticleIdList": ["10.1016/j.cell.2017.11.009", "PMC5741091", "29245013"]}, {"Citation": "Carrick S., Parker S., Thornton C.E., Ghersi D., Simes J., Wilcken N. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst. Rev. 2009;2009:CD003372. doi: 10.1002/14651858.CD003372.pub3.", "ArticleIdList": ["10.1002/14651858.CD003372.pub3", "PMC6885070", "19370586"]}, {"Citation": "Boshuizen J., Peeper D.S. Rational Cancer Treatment Combinations: An Urgent Clinical Need. Mol. Cell. 2020;78:1002\u20131018. doi: 10.1016/j.molcel.2020.05.031.", "ArticleIdList": ["10.1016/j.molcel.2020.05.031", "32559422"]}, {"Citation": "Delbaldo C., Michiels S., Syz N., Soria J.-C., le Chevalier T., Pignon J.-P. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: A meta-analysis. JAMA. 2004;292:470\u2013484. doi: 10.1001/jama.292.4.470.", "ArticleIdList": ["10.1001/jama.292.4.470", "15280345"]}, {"Citation": "Riechelmann R.P., Tannock I.F., Wang L., Saad E.D., Taback N.A., Krzyzanowska M.K. Potential drug interactions and duplicate prescriptions among cancer patients. J. Natl. Cancer Inst. 2007;99:592\u2013600. doi: 10.1093/jnci/djk130.", "ArticleIdList": ["10.1093/jnci/djk130", "17440160"]}, {"Citation": "Szumilak M., Wiktorowska-Owczarek A., Stanczak A. Hybrid Drugs\u2014A Strategy for Overcoming Anticancer Drug Resistance? Molecules. 2021;26:2601. doi: 10.3390/molecules26092601.", "ArticleIdList": ["10.3390/molecules26092601", "PMC8124695", "33946916"]}, {"Citation": "Hasan M., Leak R.K., Stratford R.E., Zlotos D.P., Witt-Enderby P.A. Drug conjugates\u2014An emerging approach to treat breast cancer. Pharmacol. Res. Perspect. 2018;6:e00417. doi: 10.1002/prp2.417.", "ArticleIdList": ["10.1002/prp2.417", "PMC6032357", "29983986"]}, {"Citation": "Li C., Wallace S. Polymer-drug conjugates: Recent development in clinical oncology. Adv. Drug Deliv. Rev. 2008;60:886\u2013898. doi: 10.1016/j.addr.2007.11.009.", "ArticleIdList": ["10.1016/j.addr.2007.11.009", "PMC2432086", "18374448"]}, {"Citation": "Marshall D.J., Harried S.S., Murphy J.L., Hall C.A., Shekhani M.S., Pain C., Lyons C.A., Chillemi A., Malavasi F., Pearce H.L., et al. Extracellular Antibody Drug Conjugates Exploiting the Proximity of Two Proteins. Mol. Ther. 2016;24:1760\u20131770. doi: 10.1038/mt.2016.119.", "ArticleIdList": ["10.1038/mt.2016.119", "PMC5112037", "27434591"]}, {"Citation": "Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs. 2016;8:659\u2013671. doi: 10.1080/19420862.2016.1156829.", "ArticleIdList": ["10.1080/19420862.2016.1156829", "PMC4966843", "27045800"]}, {"Citation": "Mercadante S. The use of anti-inflammatory drugs in cancer pain. Cancer Treat. Rev. 2001;27:51\u201361. doi: 10.1053/ctrv.2000.0192.", "ArticleIdList": ["10.1053/ctrv.2000.0192", "11237777"]}, {"Citation": "Vardy J., Agar M. Nonopioid drugs in the treatment of cancer pain. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2014;32:1677\u20131690. doi: 10.1200/JCO.2013.52.8356.", "ArticleIdList": ["10.1200/JCO.2013.52.8356", "24799483"]}, {"Citation": "Hamoya T., Fujii G., Miyamoto S., Takahashi M., Totsuka Y., Wakabayashi K., Toshima J., Mutoh M. Effects of NSAIDs on the risk factors of colorectal cancer: A mini review. Genes Environ. Off. J. Jpn. Environ. Mutagen Soc. 2016;38:6. doi: 10.1186/s41021-016-0033-0.", "ArticleIdList": ["10.1186/s41021-016-0033-0", "PMC4918106", "27350826"]}, {"Citation": "Moris D., Kontos M., Spartalis E., Fentiman I.S. The Role of NSAIDs in Breast Cancer Prevention and Relapse: Current Evidence and Future Perspectives. Breast Care. 2016;11:339\u2013344. doi: 10.1159/000452315.", "ArticleIdList": ["10.1159/000452315", "PMC5122986", "27920627"]}, {"Citation": "Plano D., Karelia D.N., Pandey M.K., Spallholz J.E., Amin S., Sharma A.K. Design, Synthesis, and Biological Evaluation of Novel Selenium (Se-NSAID) Molecules as Anticancer Agents. J. Med. Chem. 2016;59:1946\u20131959. doi: 10.1021/acs.jmedchem.5b01503.", "ArticleIdList": ["10.1021/acs.jmedchem.5b01503", "26750401"]}, {"Citation": "Weninger A., Baecker D., Obermoser V., Egger D., Wurst K., Gust R. Synthesis and Biological Evaluation of Zeise\u2019s Salt Derivatives with Acetylsalicylic Acid Substructure. Int. J. Mol. Sci. 2018;19:1612. doi: 10.3390/ijms19061612.", "ArticleIdList": ["10.3390/ijms19061612", "PMC6032411", "29848978"]}, {"Citation": "Baecker D., Obermoser V., Kirchner E.A., Hupfauf A., Kircher B., Gust R. Fluorination as tool to improve bioanalytical sensitivity and COX-2-selective antitumor activity of cobalt alkyne complexes. Dalton Trans. 2019;48:15856\u201315868. doi: 10.1039/C9DT03330K.", "ArticleIdList": ["10.1039/C9DT03330K", "31617517"]}, {"Citation": "Banekovich C., Ott I., Koch T., Matuszczak B., Gust R. Synthesis and biological activities of novel dexibuprofen tetraacetylriboflavin conjugates. Bioorg. Med. Chem. Lett. 2007;17:683\u2013687. doi: 10.1016/j.bmcl.2006.10.087.", "ArticleIdList": ["10.1016/j.bmcl.2006.10.087", "17110105"]}, {"Citation": "Curci A., Denora N., Iacobazzi R.M., Ditaranto N., Hoeschele J.D., Margiotta N., Natile G. Synthesis, characterization, and in vitro cytotoxicity of a Kiteplatin-Ibuprofen Pt(IV) prodrug. Inorg. Chim. Acta. 2018;472:221\u2013228. doi: 10.1016/j.ica.2017.07.019.", "ArticleIdList": ["10.1016/j.ica.2017.07.019"]}, {"Citation": "Zhang L., Liu L., Zheng C., Wang Y., Nie X., Shi D., Chen Y., Wei G., Wang J. Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells. Eur. J. Med. Chem. 2017;131:81\u201391. doi: 10.1016/j.ejmech.2017.03.011.", "ArticleIdList": ["10.1016/j.ejmech.2017.03.011", "28301815"]}, {"Citation": "Garrido M., Gonz\u00e1lez-Arenas A., Camacho-Arroyo I., Cabeza M., Alcaraz B., Bratoeff E. Effect of new hybrids based on 5,16-pregnadiene scaffold linked to an anti-inflammatory drug on the growth of a human astrocytoma cell line (U373) Eur. J. Med. Chem. 2015;93:135\u2013141. doi: 10.1016/j.ejmech.2015.01.048.", "ArticleIdList": ["10.1016/j.ejmech.2015.01.048", "25666913"]}, {"Citation": "Gouda A.M., Ali H.I., Almalki W.H., Azim M.A., Abourehab M.A.S., Abdelazeem A.H. Design, synthesis, and biological evaluation of some novel pyrrolizine derivatives as COX inhibitors with anti-inflammatory/analgesic activities and low ulcerogenic liability. Molecules. 2016;21:201. doi: 10.3390/molecules21020201.", "ArticleIdList": ["10.3390/molecules21020201", "PMC6273963", "26867188"]}, {"Citation": "Attalah K.M., Abdalla A.N., Aslam A., Ahmed M., Abourehab M.A.S., ElSawy N.A., Gouda A.M. Ethyl benzoate bearing pyrrolizine/indolizine moieties: Design, synthesis and biological evaluation of anti-inflammatory and cytotoxic activities. Bioorg. Chem. 2020;94:103371. doi: 10.1016/j.bioorg.2019.103371.", "ArticleIdList": ["10.1016/j.bioorg.2019.103371", "31708230"]}, {"Citation": "Gouda A.M., Beshr E.A., Almalki F.A., Halawah H.H., Taj B.F., Alnafaei A.F., Alharazi R.S., Kazi W.M., AlMatrafi M.M. Arylpropionic acid-derived NSAIDs: New insights on derivatization, anticancer activity and potential mechanism of action. Bioorg. Chem. 2019;92:103224. doi: 10.1016/j.bioorg.2019.103224.", "ArticleIdList": ["10.1016/j.bioorg.2019.103224", "31491568"]}, {"Citation": "Dhakane V.D., Chavan H.V., Thakare V.N., Adsul L.K., Shringare S.N., Bandgar B.P. Novel ibuprofen prodrugs with improved pharmacokinetics and non-ulcerogenic potential. Med. Chem. Res. 2014;23:503\u2013517. doi: 10.1007/s00044-013-0639-8.", "ArticleIdList": ["10.1007/s00044-013-0639-8"]}, {"Citation": "Shanbhag V.R., Crider A.M., Gokhale R., Harpalani A., Dick R.M. Ester and amide prodrugs of ibuprofen and naproxen: Synthesis, anti-inflammatory activity, and gastrointestinal toxicity. J. Pharm. Sci. 1992;81:149\u2013154. doi: 10.1002/jps.2600810210.", "ArticleIdList": ["10.1002/jps.2600810210", "1545354"]}, {"Citation": "Marjanovi\u0107 M., Zorc B., Pejnovi\u0107 L., Zovko M., Kralj M. Fenoprofen and Ketoprofen Amides as Potential Antitumor Agents. Chem. Biol. Drug Des. 2007;69:222\u2013226. doi: 10.1111/j.1747-0285.2007.00494.x.", "ArticleIdList": ["10.1111/j.1747-0285.2007.00494.x", "17441909"]}, {"Citation": "Almalki F.A., Abdalla A.N., Shawky A.M., el Hassab M.A., Gouda A.M. In Silico Approach Using Free Software to Optimize the Antiproliferative Activity and Predict the Potential Mechanism of Action of Pyrrolizine-Based Schiff Bases. Molecules. 2021;26:4002. doi: 10.3390/molecules26134002.", "ArticleIdList": ["10.3390/molecules26134002", "PMC8271847", "34209011"]}, {"Citation": "Shawky A.M., Abdalla A.N., Ibrahim N.A., Abourehab M.A.S., Gouda A.M. Discovery of new pyrimidopyrrolizine/indolizine-based derivatives as P-glycoprotein inhibitors: Design, synthesis, cytotoxicity, and MDR reversal activities. Eur. J. Med. Chem. 2021;218:113403. doi: 10.1016/j.ejmech.2021.113403.", "ArticleIdList": ["10.1016/j.ejmech.2021.113403", "33823396"]}, {"Citation": "Shawky A.M., Ibrahim N.A., Abdalla A.N., Abourehab M.A.S., Gouda A.M. Novel pyrrolizines bearing 3,4,5-trimethoxyphenyl moiety: Design, synthesis, molecular docking, and biological evaluation as potential multi-target cytotoxic agents. J. Enzym. Inhib. Med. Chem. 2021;36:1313\u20131333. doi: 10.1080/14756366.2021.1937618.", "ArticleIdList": ["10.1080/14756366.2021.1937618", "PMC8221158", "34154478"]}, {"Citation": "Shawky A.M., Abourehab M.A.S., Abdalla A.N., Gouda A.M. Optimization of pyrrolizine-based Schiff bases with 4-thiazolidinone motif: Design, synthesis and investigation of cytotoxicity and anti-inflammatory potency. Eur. J. Med. Chem. 2020;185:111780. doi: 10.1016/j.ejmech.2019.111780.", "ArticleIdList": ["10.1016/j.ejmech.2019.111780", "31655429"]}, {"Citation": "Shawky A.M., Ibrahim N.A., Abourehab M.A.S., Abdalla A.N., Gouda A.M. Pharmacophore-based virtual screening, synthesis, biological evaluation, and molecular docking study of novel pyrrolizines bearing urea/thiourea moieties with potential cytotoxicity and CDK inhibitory activities. J. Enzym. Inhib. Med. Chem. 2021;36:15\u201333. doi: 10.1080/14756366.2020.1837124.", "ArticleIdList": ["10.1080/14756366.2020.1837124", "PMC7594867", "33103497"]}, {"Citation": "Amujuri D., Siva B., Poornima B., Sirisha K., Sarma A.V.S., Lakshma Nayak V., Tiwari A.K., Purushotham U., Suresh Babu K. Synthesis and biological evaluation of Schizandrin derivatives as potential anti-cancer agents. Eur. J. Med. Chem. 2018;149:182\u2013192. doi: 10.1016/j.ejmech.2018.02.066.", "ArticleIdList": ["10.1016/j.ejmech.2018.02.066", "29501940"]}, {"Citation": "Mazaleuskaya L.L., Theken K.N., Gong L., Thorn C.F., FitzGerald G.A., Altman R.B., Klein T.E. PharmGKB summary: Ibuprofen pathways. Pharmacogenet. Genom. 2015;25:96\u2013106. doi: 10.1097/FPC.0000000000000113.", "ArticleIdList": ["10.1097/FPC.0000000000000113", "PMC4355401", "25502615"]}, {"Citation": "Alkatheeri N.A., Wasfi I.A., Lambert M. Pharmacokinetics and metabolism of ketoprofen after intravenous and intramuscular administration in camels. J. Vet. Pharmacol. Ther. 1999;22:127\u2013135. doi: 10.1046/j.1365-2885.1999.00193.x.", "ArticleIdList": ["10.1046/j.1365-2885.1999.00193.x", "10372597"]}, {"Citation": "Qandil A.M. Prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs), more than meets the eye: A critical review. Int. J. Mol. Sci. 2012;13:17244\u201317274. doi: 10.3390/ijms131217244.", "ArticleIdList": ["10.3390/ijms131217244", "PMC3546748", "23247285"]}, {"Citation": "Selinsky B.S., Gupta K., Sharkey C.T., Loll P.J. Structural analysis of NSAID binding by prostaglandin H2 synthase: Time-dependent and time-independent inhibitors elicit identical enzyme conformations. Biochemistry. 2001;40:5172\u20135180. doi: 10.1021/bi010045s.", "ArticleIdList": ["10.1021/bi010045s", "11318639"]}, {"Citation": "Kurumbail R.G., Stevens A.M., Gierse J.K., McDonald J.J., Stegeman R.A., Pak J.Y., Gildehaus D., Miyashiro J.M., Penning T.D., Seibert K., et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 1996;384:644\u2013648. doi: 10.1038/384644a0.", "ArticleIdList": ["10.1038/384644a0", "8967954"]}, {"Citation": "Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., Olson A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 2009;30:2785\u20132791. doi: 10.1002/jcc.21256.", "ArticleIdList": ["10.1002/jcc.21256", "PMC2760638", "19399780"]}, {"Citation": "Mohassab A.M., Hassan H.A., Abdelhamid D., Gouda A.M., Gomaa H.A.M., Youssif B.G.M., Radwan M.O., Fujita M., Otsuka M., Abdel-Aziz M. New quinoline/1,2,4-triazole hybrids as dual inhibitors of COX-2/5-LOX and inflammatory cytokines: Design, synthesis, and docking study. J. Mol. Struct. 2021;1244:130948. doi: 10.1016/j.molstruc.2021.130948.", "ArticleIdList": ["10.1016/j.molstruc.2021.130948"]}, {"Citation": "Dassault Systems BIOVIA . Discovery Studio Visualizer, v16.1.0.15350. Dassault Systems; San Diego, CA, USA: 2016."}, {"Citation": "Reichel A., Lienau P. Pharmacokinetics in Drug Discovery: An Exposure-Centred Approach to Optimising and Predicting Drug Efficacy and Safety. Handb. Exp. Pharmacol. 2016;232:235\u2013260. doi: 10.1007/164_2015_26.", "ArticleIdList": ["10.1007/164_2015_26", "26330260"]}, {"Citation": "Tuntland T., Ethell B., Kosaka T., Blasco F., Zang R.X., Jain M., Gould T., Hoffmaster K. Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research. Front. Pharmacol. 2014;5:174. doi: 10.3389/fphar.2014.00174.", "ArticleIdList": ["10.3389/fphar.2014.00174", "PMC4112793", "25120485"]}, {"Citation": "Daina A., Michielin O., Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017;7:42717. doi: 10.1038/srep42717.", "ArticleIdList": ["10.1038/srep42717", "PMC5335600", "28256516"]}, {"Citation": "Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001;46:3\u201326. doi: 10.1016/S0169-409X(00)00129-0.", "ArticleIdList": ["10.1016/S0169-409X(00)00129-0", "11259830"]}, {"Citation": "Zhao Y.H., Abraham M.H., Le J., Hersey A., Luscombe C.N., Beck G., Sherborne B., Cooper I. Rate-Limited Steps of Human Oral Absorption and QSAR Studies. Pharm. Res. 2002;19:1446\u20131457. doi: 10.1023/A:1020444330011.", "ArticleIdList": ["10.1023/A:1020444330011", "12425461"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "10", "Day": "10"}, {"Year": "2021", "Month": "10", "Day": "27"}, {"Year": "2021", "Month": "10", "Day": "27"}, {"Year": "2021", "Month": "11", "Day": "13", "Hour": "1", "Minute": "13"}, {"Year": "2021", "Month": "11", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "12", "Day": "15", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "10", "Day": "30"}], "PublicationStatus": "epublish", "ArticleIdList": ["34770990", "PMC8588198", "10.3390/molecules26216582", "molecules26216582"]}}], "PubmedBookArticle": []}